Macomics is an immuno-oncology company that develops medicines to modulate macrophages for the treatment of cancer, by bringing together cancer biologists. Its target discovery platform enables the identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology. It is progressing a diversified portfolio of therapies targeting disease-specific tumor-associated macrophages (‘TAMs’) towards the clinic.